AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

TribeNews
By TribeNews 11 Views Add a Comment
0 Min Read

MedPage Today) — At the recent American Society of Hematology (ASH) annual meeting, data from a phase I trial of AZD0486 — a novel CD19xCD3 bispecific T-cell engager — showed high response rates and encouraging safety in relapsed/refractory…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app